Results 171 to 180 of about 10,751 (182)

Ramucirumab, a Second-Line Option for Patients With Hepatocellular Carcinoma: A Review of the Evidence

Cancer Management and Research, 2020
Massimo Di Maio, Emmanuele de Luca
exaly  

Ramucirumab Monotherapy for Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (REGARD): An International, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial

Lancet, The, 2014
Giuseppe Aprile, Eldar Topuzov, Lucas V. dos Santos   +2 more
exaly  

Efficacy and Tolerability of Ramucirumab Monotherapy or in Combination With Paclitaxel in Gastric Cancer Patients From the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG)

Gastric Cancer, 2018
Byoung Yong Shim, Hye Sook Han, Minkyu Jung   +2 more
exaly  

Quality-of-Life and Performance Status Results From the Phase III RAINBOW Study of Ramucirumab Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Previously Treated Gastric or Gastroesophageal Junction Adenocarcinoma

Annals of Oncology, 2016
David Cunningham, György Bodoky, Eric Van Cutsem   +2 more
exaly  

Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Platinum-Based Therapy (RANGE): A Randomised, Double-Blind, Phase 3 Trial

Lancet, The, 2017
Ulka Vaishampayan, Daniel P Petrylak, Jean-Pascal Machiels   +2 more
exaly  

Sequential Therapy With Ramucirumab And/Or Checkpoint Inhibitors for Non-Small-Cell Lung Cancer in Routine Practice

Future Oncology, 2019
Cliff Molife, Malika Mahoui, Lisa M Hess
exaly  

Benefit with ramucirumab in mesothelioma

Nature Reviews Clinical Oncology, 2021
openaire   +2 more sources

Subgroup Analysis in RAISE: A Randomized, Double-Blind Phase III Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progression

Annals of Oncology, 2016
Josep Tabernero Caturla, Rocío García-Carbonero, György Bodoky   +2 more
exaly  

Efficacy and Safety of Ramucirumab Plus Carboplatin and Paclitaxel in Untreated Metastatic Thymic Carcinoma: RELEVENT Phase II Trial (NCT03921671)

Annals of Oncology
T Beninato, S Manglaviti, F G M de Braud
exaly  

Population Pharmacokinetic Meta-Analysis of Ramucirumab in Cancer Patients

British Journal of Clinical Pharmacology, 2017
Michael Heathman, Lisa O'brien
exaly